Omega Fund Management LLC Has $7.91 Million Position in enGene Holdings Inc. $ENGN

Omega Fund Management LLC raised its holdings in shares of enGene Holdings Inc. (NASDAQ:ENGN) by 66.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 876,357 shares of the company’s stock after buying an additional 350,000 shares during the period. enGene comprises approximately 2.8% of Omega Fund Management LLC’s investment portfolio, making the stock its 7th biggest position. Omega Fund Management LLC’s holdings in enGene were worth $7,914,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Cresset Asset Management LLC bought a new stake in enGene during the second quarter worth approximately $36,000. Raymond James Financial Inc. boosted its holdings in enGene by 383.6% during the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after buying an additional 7,932 shares in the last quarter. Paloma Partners Management Co bought a new stake in enGene during the second quarter worth approximately $38,000. PFS Partners LLC boosted its holdings in enGene by 22.2% during the fourth quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock worth $99,000 after buying an additional 2,000 shares in the last quarter. Finally, Hudson Bay Capital Management LP bought a new stake in enGene during the third quarter worth approximately $76,000. 64.16% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on ENGN shares. Guggenheim cut shares of enGene from a “buy” rating to a “neutral” rating in a report on Thursday, May 7th. Leerink Partners lowered shares of enGene from an “outperform” rating to a “market perform” rating and set a $2.00 price objective for the company. in a research note on Friday, May 8th. Morgan Stanley lowered shares of enGene from an “overweight” rating to an “equal weight” rating in a research note on Friday, May 8th. UBS Group decreased their price objective on shares of enGene from $9.00 to $2.00 and set a “neutral” rating for the company in a research note on Thursday, May 14th. Finally, HC Wainwright decreased their price objective on shares of enGene from $6.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday. Four equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $12.50.

enGene Trading Down 1.1%

enGene stock opened at $1.75 on Wednesday. The company has a 50 day moving average price of $4.21 and a 200 day moving average price of $7.15. enGene Holdings Inc. has a 52 week low of $1.40 and a 52 week high of $12.25. The company has a debt-to-equity ratio of 0.09, a quick ratio of 11.75 and a current ratio of 11.75. The firm has a market capitalization of $117.23 million, a price-to-earnings ratio of -0.81 and a beta of -0.30.

enGene (NASDAQ:ENGN) last posted its quarterly earnings data on Monday, June 15th. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.91. During the same quarter last year, the business posted $0.51 earnings per share. Research analysts forecast that enGene Holdings Inc. will post -2.02 EPS for the current year.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.